CDC: No deaths among young U.S. adults with myocarditis after Pfizer injection

Aug 30 (Reuters) – No deaths have been reported among young U.S. adults who developed rare heart inflammation known as myocarditis after receiving the Pfizer Inc / BioNTech (PFE.N) vaccine, COVID-19, the Centers for Disease Control and Prevention said Monday.

Myocarditis is known to occur at a higher rate in those who contract COVID-19 than in those who have been vaccinated with the Pfizer / BioNTech vaccine or that produced by Moderna Inc (MRNA.O).

None of the 384 people aged 16 to 29 who developed heart disease after receiving the Pfizer / BioNTech vaccine have died, the Atlanta-based health agency said at a meeting of its advisory committee on vaccination practices.

He added that no cases of death had been reported among people in this age group who had myocarditis after receiving the Moderna vaccine.

The risk of myocarditis ranges from 18.5 cases per 1 million doses after a second dose of Pfizer / BioNTech vaccine to 20.2 cases per million doses after a second dose of Moderna vaccine in people aged 18 to 24 years , a higher risk than in other age groups. The risk was also significantly higher in men than in women, according to CDC data.

A total of 2,574 preliminary cases of myocarditis or pericarditis, another rare type of heart inflammation, have been reported among those who received COVID-19 vaccines in the United States, with about half among those who received the Pfizer / BioNTech vaccine, about 20% among those who received the Moderna vaccine and the remainder among those who received the Johnson & Johnson vaccine (JNJ.N).

Report by Manas Mishra in Bengaluru Editing by Paul Simao

Our Standards: Thomson Reuters Trust Principles.